In Bloomberg Law, Attorneys Analyze Transactional Implications of Inflation Reduction Act’s Drug Pricing Provisions
In a Bloomberg Law article, attorneys examined the transactional implications of the Inflation Reduction Act of 2022 that is poised to reshare Medicare pricing, the reimbursement of drugs, commercial practices and the drug development landscape.
The article provides an overview of the IRA’s drug price negotiation program and discusses possible downstream industry effects, including deal impacts, with the aim of providing a set of IRA drug pricing and deal considerations to help find solutions and close deals.
The article was authored by life sciences and IP transactions partner David McIntosh, health care partner Margaux Hall, who leads the firm’s drug pricing and price reporting group, and corporate associate Kyle Connors.
Reproduced with permission. Published March 14, 2023. Copyright 2023 by Bloomberg Industry Group, Inc. (800-372-1033).